Shots:

• The approval is based on trials assessing KW-6002 vs PBO across EU- the US and Japan in patients with PD taking a stable dose of levodopa-based regimens with/out other PD medications
• The candidate will serve as an adjunctive treatment to the PD patients which is validated by the EMA and is now under review
• Istradefylline is a selective adenosine A2A receptor antagonist administered orally and is approved in Japan & the US in Mar 2013- & Aug 2019- to improve “wearing-off” phenomenon in patients with PD on levodopa-containing preparations and as an adjunctive treatment to levodopa/carbidopa in adults with PD experiencing “off” episodes respectively

Click here to read full press release/ article | Ref: Kyowa Kirin | Image: Twitter